Virus Details


VHFID1653

Host Factor Information

Gene Name RRP1
HF Protein Name Ribosomal RNA processing protein 1 homolog A
HF Function Proviral host factor
Uniprot ID P56182
Protein Sequence View Fasta Sequence
NCBI Gene ID 8568
Host Factor (HF) Name in Paper D21S2056E
Gene synonyms D21S2056E NNP1 NOP52 RRP1A
Ensemble Gene ID ENSG00000160214
Ensemble Transcript ENST00000497547
KEGG ID Go to KEGG Database
Gene Ontology ID(s) GO:0003723, GO:0005634, GO:0005730, GO:0006364, GO:0030687, GO:0030688,
MINT ID P56182
STRING Click to see interaction map
GWAS Analysis Click to see gwas analysis
OMIM ID 610653
PANTHER ID PTHR13026
PDB ID(s) N.A.,
pfam ID PF05997,
Drug Bank ID N.A.,
ChEMBL ID N.A.
Organism Homo sapiens (Human)

Pathogen Information

Virus Name Chikungunya virus
Virus Short Name CHIKV
Order Unassigned
Virus Family Togaviridae
Virus Subfamily N.A.
Genus Alphavirus
Species Chikungunya virus
Host Human, mammals,mosquitoes and birds
Cell Tropism N.A.
Associated Disease Fever and joint pain
Mode of Transmission By infected mosquito
VIPR DB link https://www.viprbrc.org/brc/vipr_allSpecies_search.spg?method=SubmitForm&decorator=toga
ICTV DB link https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/275/togaviridae
Virus Host DB link N.A.

Publication Information

Paper Title A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs
Author's Name Alexander Karlas, Stefano Berre, Therese Couderc, Margus Varjak, Peter Braun Michael Meyer, Nicolas Gangneux, Liis Karo-Astover, Friderike Weege, Martin Raftery, Gu ?nther Scho ?nrich, Uwe Klemm, Anne Wurzlbauer, Franz Bracher, Andres Merits, Thomas F. Meyer & Marc Lecuit
Journal Name nature communications
Pubmed ID 27177310
Abstract Chikungunya virus (CHIKV) is a globally spreading alphavirus against which there is no commercially available vaccine or therapy. Here we use a genome-wide siRNA screen to identify 156 proviral and 41 antiviral host factors affecting CHIKV replication. We analyse the cellular pathways in which human proviral genes are involved and identify druggable targets. Twenty-one small-molecule inhibitors, some of which are FDA approved, targeting six proviral factors or pathways, have high antiviral activity in vitro, with low toxicity. Three identified inhibitors have prophylactic antiviral effects in mouse models of chikungunya infection. Two of them, the calmodulin inhibitor pimozide and the fatty acid synthesis inhibitor TOFA, have a therapeutic effect in vivo when combined. These results demonstrate the value of loss-of-function screening and pathway analysis for the rational identification of small molecules with therapeutic potential and pave the way for the development of new, host-directed, antiviral agents.
Used Model A549 and HEK-293T cells
DOI 10.1038/ncomms11320